The beta version of Bluesky app created by Jack Dorsey is available now
EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Study results
AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
24.10.2022 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
PREVYMIS showed non-inferior efficacy and more favorable safety profile compared to standard of care; MSD presented results in late breaking oral presentation at IDWeek 2022.
Based on these phase 3 results, MSD plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) by the end of this year.
PREVYMIS is a first-in-class antiviral agent that was approved by the U.S. FDA for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
PREVYMIS was developed by AiCuris through phase 2 studies prior to licensing the antiviral medicine to MSD in 2012. AiCuris is eligible to receive milestone payments and royalties on net sales of PREVYMIS.
Wuppertal, Germany, October 24, 2022 – AiCuris Anti-infective Cures AG, a leading clinical stage pharmaceutical company in the development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases, announced today that its licensing partner MSD (tradename of Merck & Co., Inc., Rathway, N.J., USA, (NYSE: MRK)) presented positive findings from a phase 3 clinical trial that assessed safety and efficacy of PREVYMIS (letermovir) compared to valganciclovir for cytomegalovirus (CMV) prophylaxis in 601 adult kidney transplant recipients at high risk for CMV disease. The data were presented during a late-breaking oral session at the IDWeek Annual Meeting (Abstract # LB2307). Based on these findings, MSD plans to submit a sNDA to the FDA by the end of this year.
According to the MSD announcement, the trial results met the primary endpoint demonstrating that PREVYMIS was effective and non-inferior to valganciclovir for preventing CMV disease. At 52 weeks following kidney transplant, 10.4% (n=30) of the PREVYMIS group developed CMV disease versus 11.8% (n=35) of the valganciclovir group (stratum adjusted difference= -1.4, [95% CI, -6.5, 3.8]). PREVYMIS had a more favorable safety profile compared to valganciclovir, with fewer drug-related adverse events and study drug discontinuations due to adverse events reported in the PREVYMIS group (4.1%; n=12) versus 13.5% (n=40) in the valganciclovir group; (95% CI, −14.1, −4.9). Specifically, PREVYMIS-treated patients had significantly less myelotoxicity, as measured by rates of leukopenia or neutropenia, compared to valganciclovir-treated patients; 26.0% (n=76) versus 64.0% (n=190), (95% CI, -45.1, -30.3; p-value <0.0001).
“We are excited that our partner MSD built on the initial success of PREVYMIS in the hematological transplant setting and showed, that PREVYMIS is effectively preventing CMV disease with significantly less toxicities compared to standard of care in adult kidney transplant recipients,” said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG. “This important milestone further validates our ability to successfully develop innovative therapies that have the potential to truly make a difference for patients suffering from serious infectious diseases.”
In the phase 3 study, 601 patients were randomized (1:1) to receive once a day either 480 mg of PREVYMIS (n=301) or 900 mg of valganciclovir (n=300), within 7 days post-kidney transplant through 28 weeks (~200 days) post-transplant, with follow-up through 52 weeks. The primary endpoint was the proportion of participants with CMV disease adjudicated by an independent, blinded committee. The median age of participants was 52 years in the PREVYMIS study group and 51 years in the valganciclovir study group. Participants were stratified by use/non-use of lymphocyte-depleting induction immunotherapy.
PREVYMIS is a first-in-class antiviral agent that was approved by the U.S. FDA in 2017 and is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
About CMV and Treatment
CMV is a common virus that infects people of all ages. Many adults in the United States are CMV seropositive, meaning they have CMV antibodies in their blood, indicating a previous exposure to or primary infection with CMV. People with normal immune systems rarely develop CMV symptoms after initial infection, with the virus typically remaining inactive or latent in the body for life. A weakened immune system may give the virus a chance to reactivate, potentially leading to symptomatic disease or a secondary infection due to other pathogens. When a transplant recipient who is CMV seronegative receives an organ from a donor who is CMV seropositive, the transplant recipient can get CMV from the donated organ. CMV disease can lead to end-organ damage, including gastrointestinal tract disease, pneumonia or retinitis. Transplant recipients who develop CMV infection post-transplant are at increased risk for transplant failure and death. CMV prophylaxis with certain existing antivirals has been associated with drug-specific effects, including myelosuppression and renal toxicity.
About PREVYMIS® (letermovir)
PREVYMIS is the only drug approved in the United States for prophylaxis of CMV infection and disease in adults who are CMV-seropositive and have received an allogeneic HSCT. PREVYMIS is also approved in more than 60 countries outside of the United States, including EU member states, Canada, Japan and China. PREVYMIS is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex. Cross resistance is not likely with drugs outside of this class. PREVYMIS is fully active against viral populations with substitutions conferring resistance to CMV DNA polymerase inhibitors. These DNA polymerase inhibitors are fully active against viral populations with substitutions conferring resistance to PREVYMIS. PREVYMIS has no activity against other viruses.
Under an agreement signed in 2012, MSD purchased worldwide rights to develop and commercialize letermovir from AiCuris Anti-infective Cures AG.
About AiCuris Anti-infective Cures AG
AiCuris, a clinical-stage biopharmaceutical company focuses on the discovery and development of drugs targeting infectious diseases. PREVYMIS® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, US, Japan, China and other parts of the world for the prevention of human CMV infections in adults who received allogeneic hematopoietic stem cell transplantation. AiCuris has a broad pipeline of clinical-stage and pre-clinical anti-viral and anti-bacterial product candidates. Its wholly owned lead asset, pritelivir, targeting single- or double-resistant herpes simplex virus (HSV) infections, is in phase 3 clinical development. Additional candidates are in development for the treatment of viruses, such as hepatitis B virus (HBV), adenoviruses and BK virus (BKV), as well as SARS-CoV2 and other viruses with pandemic potential. Moreover, AiCuris seeks to develop innovative treatment options for indications with high medical need, including life-threatening, multidrug-resistant, hospital-treated pathogens. Product candidates for antimicrobial resistance (AMR), diabetic foot ulcers and sepsis are in pre-clinical development.
AiCuris is supported by a strong shareholder base, including lead investor SANTO Holding.
For more information, please visit www.aicuris.com.
Follow us on LinkedIn.
Contacts:
Company:
AiCuris Anti-infective Cures AG
Katja Woestenhemke
Phone: +49 202 317 63 0
Email: info@aicuris.com
Media relations
MC Services AG
Dr. Solveigh Mähler
Phone: +49 211 529 252 19
Email: aicuris@mc-services.eu
24.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
STOCKHOLM, SWEDEN, October 24, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today its participation in a seed financing of Henlez, a privately owned Danish company focusing on a development project directed towards the chronic dermatological condition hidradenitis suppurativa. The global market for treatments of hidradenitis suppurativa is projected to reach USD 1.8 billion by 2028. Henlez’s pre-clinical lead development program, HEN-001, is an enzyme-based, topical applica
Mathilde Lheureux Takes the Lead of Free2move eSolutions as New CEO AMSTERDAM, October 24, 2022 – Free2move eSolutions, a joint venture between NHOA Group (NHOA.PA) and Stellantis N.V., announces the appointment of Mathilde Lheureux as Chief Executive Officer. The board of directors has unanimously appointed Mathilde Lheureux Chief Executive Officer and thanked Roberto Di Stefano for his great work in such a complex context. Roberto Di Stefano will continue at Stellantis in another position. “In
LISBON (Reuters) -Portuguese oil and gas company Galp Energia reported a 16% increase in adjusted third-quarter profit on Monday, thanks to soaring oil prices and a near-doubling of its refining margin, but its shares fell on more conservative guidance. Oil and gas companies around the world received a boost after Russia's invasion of Ukraine sent energy prices soaring just as demand was rapidly recovering with the lifting of pandemic restrictions. Galp's July-September adjusted net profit was 187 million euros, up from 161 million euros a year earlier and above the 177 million euros expected by 21 analysts polled by the company.
Around one in four German companies currently seeking new loans are reporting restraint from lenders as high inflation and concerns over energy supply rattle Europe's largest economy, according to a survey published on Monday. The figure – 24.3% – is the highest seen since 2017, said the Ifo institute, which conducted the survey. "The difficult economic climate is currently making banks more cautious," said Klaus Wohlrabe, Ifo's head of surveys.
LONDON (Reuters) -Education group Pearson said an "outstanding" performance in English language learning had helped deliver 7% growth in underlying sales in the last nine months, ahead of market expectations and keeping it on track for the full year. The British company reported 28% growth in English language courses, with demand boosted by the reopening of borders after the pandemic. Chief Executive Andy Bird said the company was "very encouraged" by recent enrollment data in the United States that showed a 1.1% decline, which analysts said was about half the rate of a year earlier.
The deadline affects 'everyday' stamps featuring the late Queen's profile, Royal Mail said.
I’m exploring some of the FTSE index's cheapest dividend stocks. Here's one I plan to cling onto, and one I wouldn't touch with a bargepole. The post A cheap FTSE 100 dividend share I’m holding and one I’d sell! appeared first on The Motley Fool UK.
Overseas business groups in China expressed on Monday wariness about President's Xi Jinping's newly unveiled leadership team and his stated priorities, with some urging against greater state intervention in the market. Eric Zheng, president of the American Chamber of Commerce in Shanghai, told Reuters the chamber was "encouraged" by a commitment to deepening reform and opening up expressed in Xi's speech at a Communist Party Congress that concluded on Sunday. "However, at a time when China's economy faces a challenging environment, we are concerned that the use of non-market tools such as government subsidies to support the state sector could be counterproductive," he said.
Logitech also said its chief financial officer, Nate Olmstead, will be leaving the company. Olmstead will stay on in his role as Logitech launches a search for his successor. Non-GAAP operating income plunged 26% to $156 million in the period, the second quarter of Logitech's financial year.
Recent upbeat trading statements from several companies mean the stock market could be undervaluing many businesses right now. The post Are we about to see the great stock market recovery of 2022? appeared first on The Motley Fool UK.
Shaken in the last 20 years by competition from Asia, Portugal's textile industry has found its footing again and become a major player, supplying firms not just in Europe but also in the United States.
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure that the healthcare community has access to timely, reliable and accurate COVID-19 PCR testing beyond the EUA period. Based on continuous analysis performed since the onset of the pandemic, all Roche molecular tests, including the cobas SARS-CoV-2 Qualitative test, detect all SARS-CoV-2 variants. Basel, 24
Mechanical diggers are hard at work in the bleak landscape of the Moanda open-cast mine in Gabon, using giant jaws to rip out manganese and then dump the ore into trucks with a crash.
ATHENS, Greece, Oct. 24, 2022 (GLOBE NEWSWIRE) — IMPERIAL PETROLEUM INC. (NASDAQ: IMPP, the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, announced today its unaudited financial and operating results for the third quarter ended September 30, 2022. In November 2021, StealthGas Inc. contributed to the Company four subsidiaries comprising a fleet of four tanker vessels, and the Company was spun-off from StealthGas Inc. in D
Global Spelt Market 2022-2026 The analyst has been monitoring the spelt market and it is poised to grow by $15. 29 bn during 2022-2026, accelerating at a CAGR of 4. 75% during the forecast period.New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Spelt Market 2022-2026" – https://www.reportlinker.com/p05312322/?utm_source=GNW Our report on the spelt market provides a holistic analysis, market size and forecast, trends, growth drivers, and cha
Global Hearing Aids 3D Printing Devices Market 2022-2026 The analyst has been monitoring the hearing aids 3D printing devices market and it is poised to grow by $ 384. 7 mn during 2022-2026, accelerating at a CAGR of 18.New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Hearing Aids 3D Printing Devices Market 2022-2026" – https://www.reportlinker.com/p05772592/?utm_source=GNW 15% during the forecast period. Our report on the hearing aids 3D p
As indirect dental restorations, inlays and onlays are created outside of the mouth in a lab. When a cavity is too big to be filled with a simple filling, an inlay or onlay is often employed.New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Dental Inlays & Onlays Market Size, Share & Industry Trends Analysis Report By Type, By Material, By Regional Outlook and Forecast, 2022 – 2028" – https://www.reportlinker.com/p06352724/?utm_source=GNW In
Drip Irrigation, also identified as trickle irrigation, is a sort of micro-irrigation that ensures the gradual distribution of water to the soil surface constantly over a longer period of time by means of small diameter tubes and pipes that deliver water drop by drop to the root zone of the plants via drippers.New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Drip Irrigation Market Size, Share & Industry Trends Analysis Report By Application
Global Programmatic Advertising Spending Market 2022-2026 The analyst has been monitoring the programmatic advertising spending market and it is poised to grow by $314. 27 bn during 2022-2026, accelerating at a CAGR of 26.New York, Oct. 24, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report "Global Programmatic Advertising Spending Market 2022-2026" – https://www.reportlinker.com/p03816778/?utm_source=GNW 66% during the forecast period. Our report on the programmatic a
The former chancellor’s promises from the last leadership contest provide clues to how he might act as Prime Minister.